HCPCS codes / Q / Q2053
Q2053
Brexucabtagene autoleucel, up to 200 million autologous anti-cd19 car positive viable t cells, including leukapheresis and dose preparation procedures, per therapeutic dose
- Code type
- HCPCS Level II
- Coverage
- Carrier judgment
- BETOS category
- O1E
- Pricing indicator
- 51
- Effective date
- 20210401
Verify before billing. Confirm against current official CMS HCPCS files and your payer's rules before clinical or claims use.